Estrella Immunopharma, Inc.
ESLATicker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Insider trading at Estrella Immunopharma, Inc. (ESLA) refers to stock transactions executed by corporate insiders—officers, directors, and shareholders owning more than 10% of the company. Over the past 90 days, 1 insiders have filed 3 transactions totaling $2.6K in trading activity. The most active insider is Jiandong Xu (Chief Financial Officer), contributing $2.6K across 3 transactions.
Estrella Immunopharma, Inc. insiders are currently net buyers of ESLA stock, showing bullish sentiment over the past 90 days. Executives have purchased $2.6K while selling $0, resulting in a positive net flow of $2.6K. This buying activity represents 100% of total transaction volume.
Estrella Immunopharma, Inc. has 1 active insiders who have filed SEC Form 4 transactions in the past 90 days. Jiandong Xu (Chief Financial Officer) leads with 3 transactions totaling $2.6K. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.
The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Estrella Immunopharma, Inc.'s current score of 100/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $2.6K in purchases versus $0 in sales.
The most recent insider transaction occurred on Oct 7, 2025, when Xu Jiandong (Chief Financial Officer) acquired 1,000 shares at $1.33 per share for $1.3K. This appears to be a discretionary trade.
Based on SEC Form 4 filings from the past 90 days, ESLA insider trading sentiment is currently bullish with an Alignment Score of 100/100. The net insider flow of $2.6K reflects accumulation, with 100% of volume being purchases.
SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Estrella Immunopharma, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ESLA, we track all Form 4 filings—currently showing 3 transactions from 1 insiders over 90 days.
A 10b5-1 plan allows Estrella Immunopharma, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ESLA, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ESLA appears discretionary, making insider signals more meaningful.
You can monitor Estrella Immunopharma, Inc. (ESLA) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 1 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.
Insider trading at Estrella Immunopharma, Inc. (ESLA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of shares. These individuals must report trades to the SEC within two business days. Currently, 1 insiders are actively trading ESLA stock, having executed 3 transactions in the past 90 days. The most active insider is Jiandong Xu (Chief Financial Officer), with 3 transactions totaling $2.6K.
Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Estrella Immunopharma, Inc.'s current score of 100/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $2.6K in purchases versus $0 in sales over 90 days, resulting in a net flow of $2.6K.
SEC Form 4 filings are mandatory reports that Estrella Immunopharma, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ESLA, the most common type is "P" with 3 occurrences. The most recent Form 4 was filed on Oct 7, 2025 by Xu Jiandong.
Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Estrella Immunopharma, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ESLA represents discretionary decisions with more informational value.
Track every insider move.
Before the market reacts.
Set alerts for Estrella Immunopharma, Inc. and 40,000+ other insiders.